Open access
Sep 2026
Lipocalin 13 Mitigates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Inhibiting the ADRB2/ERK Signalling Pathway.
BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by abnormalities in secreted protein biosynthesis. A comprehensive understanding of secreted proteins could lead to improved diagnostics and therapies for MASLD. This study investigates the therapeutic potential of lipocalin 13...
Xing-Liang Qin, Yu Hong, Wei-Shu Ren et al.
· Liver international (Print) · 0 citations